SCHEMBL23926337

SCHEMBL23926337

O=Cc1cccc(CCCN2CCOCC2)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.48
POLB P06746 1/20 0.48
KMT2A Q03164 4/20 0.46
MEN1 O00255 1/20 0.46
ERN1 O75460 2/20 0.44
L3MBTL1 Q9Y468 4/20 0.42
KDM4E B2RXH2 3/20 0.42
ALPI P09923 1/20 0.42
CYP2C9 P11712 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 4/20 0.40
HTT P42858 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
MPI P34949 1/20 0.40
RECQL P46063 1/20 0.40
KDM4C Q9H3R0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23926340 0.92 ERN1 (0.46) KMT2AMEN1ERN1L3MBTL1KDM4E
SCHEMBL7559226 0.83 CYP2C9 (0.61) POLBKMT2AMEN1ERN1L3MBTL1
SCHEMBL24127975 0.80 POLB (0.51) SIGMAR1POLBKMT2AMEN1L3MBTL1
SCHEMBL23926362 0.79 HRH3 (0.55) SIGMAR1ERN1
SCHEMBL6223730 0.77 POLB (0.47) SIGMAR1POLBKMT2AMEN1ERN1
SCHEMBL23926384 0.77 ERN1 (0.47) SIGMAR1KMT2AMEN1ERN1ALDH1A1
SCHEMBL23964434 0.76 SIGMAR1 (0.52) SIGMAR1POLBKMT2AMEN1KDM4E
SCHEMBL23926333 0.76 SIGMAR1 (0.61) SIGMAR1POLBKMT2AMEN1KDM4E
SCHEMBL21002293 0.74 ERN1 (0.59) KMT2AMEN1ERN1ALDH1A1SMN1; SMN2
SCHEMBL883309 0.74 ERN1 (0.50) KMT2AMEN1ERN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168408-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-04-26 EP disclosed
CN-115667256-A Compounds for treating diseases and methods of treating diseases 艾特里提治疗有限公司 2023-01-31 CN disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 SIGMAR1 3913/4885POLB 2864/4885KMT2A 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.